OTCMKTS:INNV - Innovus Pharmaceuticals Stock Price, News, & Analysis

-0.15 (-10.00 %)
(As of 06/17/2019 04:00 PM ET)
Today's Range
Now: $1.35
50-Day Range
MA: $2.29
52-Week Range
Now: $1.35
Volume22,028 shs
Average Volume8,115 shs
Market Capitalization$3.54 million
P/E RatioN/A
Dividend YieldN/A
Innovus Pharmaceuticals, Inc, a pharmaceutical company, engages in the development, licensing, and commercialization of non-prescription medicines and consumer care products in the United States. Its products include Zestra, a proprietary blend of essential oils to enhance desire, arousal, and satisfaction in women; EjectDelay, an over-the-counter monograph compliant benzocaine gel for premature ejaculation; Sensum+, a non-medicated cream for penile sensitivity; Zestra Glide, a water-based longer lasting lubricant; Vesele, a proprietary oral supplement for promoting sexual health; and Androferti, a natural supplement to support male reproductive health and sperm quality. Read More…

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Current SymbolOTCMKTS:INNV
Previous SymbolNASDAQ:INNV



Sales & Book Value

Annual Sales$23.99 million
Book Value$0.05 per share


Net Income$-8,280,000.00


Market Cap$3.54 million
Next Earnings Date8/13/2019 (Estimated)
OptionableNot Optionable

Receive INNV News and Ratings via Email

Sign-up to receive the latest news and ratings for INNV and its competitors with MarketBeat's FREE daily newsletter.

Innovus Pharmaceuticals (OTCMKTS:INNV) Frequently Asked Questions

What is Innovus Pharmaceuticals' stock symbol?

Innovus Pharmaceuticals trades on the OTCMKTS under the ticker symbol "INNV."

How were Innovus Pharmaceuticals' earnings last quarter?

Innovus Pharmaceuticals Inc (OTCMKTS:INNV) released its quarterly earnings data on Monday, April, 1st. The company reported ($0.99) EPS for the quarter, topping analysts' consensus estimates of ($1.11) by $0.12. The firm had revenue of $4.75 million for the quarter, compared to the consensus estimate of $8.13 million. Innovus Pharmaceuticals had a negative return on equity of 1,053.29% and a negative net margin of 34.02%. View Innovus Pharmaceuticals' Earnings History.

When is Innovus Pharmaceuticals' next earnings date?

Innovus Pharmaceuticals is scheduled to release their next quarterly earnings announcement on Tuesday, August 13th 2019. View Earnings Estimates for Innovus Pharmaceuticals.

What is the consensus analysts' recommendation for Innovus Pharmaceuticals?

1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Innovus Pharmaceuticals in the last year. There are currently 1 buy rating for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Innovus Pharmaceuticals.

Has Innovus Pharmaceuticals been receiving favorable news coverage?

Headlines about INNV stock have been trending somewhat positive recently, according to InfoTrie. The research firm ranks the sentiment of media coverage by monitoring more than six thousand news and blog sources in real time. The firm ranks coverage of public companies on a scale of negative five to five, with scores nearest to five being the most favorable. Innovus Pharmaceuticals earned a daily sentiment score of 1.4 on InfoTrie's scale. They also assigned media coverage about the company a news buzz of 10.0 out of 10, meaning that recent media coverage is extremely likely to have an effect on the company's share price in the immediate future. View News Stories for Innovus Pharmaceuticals.

Who are some of Innovus Pharmaceuticals' key competitors?

What other stocks do shareholders of Innovus Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Innovus Pharmaceuticals investors own include EEStor (ESU), Antares Pharma (ATRS), The Medicines (MDCO), Federal National Mortgage Association (FNMA), Frontier Communications (FTR), Republic First Bancorp (FRBK), FedEx (FDX), NVIDIA (NVDA), OvaScience (OVAS) and Pacific Premier Bancorp (PPBI).

Who are Innovus Pharmaceuticals' key executives?

Innovus Pharmaceuticals' management team includes the folowing people:
  • Dr. Bassam B. Damaj, Pres, CEO & Director (Age 51)
  • Mr. Ryan J. Selhorn CPA, VP & CFO (Age 37)
  • Mr. Randy J. Berholtz, Exec. VP of Corp. Devel., Gen. Counsel & Sec. (Age 58)
  • Mr. Christopher Stella, VP of Operations
  • Mr. Robert C. Verfurth, VP of Sales & Marketing

How do I buy shares of Innovus Pharmaceuticals?

Shares of INNV can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Innovus Pharmaceuticals' stock price today?

One share of INNV stock can currently be purchased for approximately $1.35.

How big of a company is Innovus Pharmaceuticals?

Innovus Pharmaceuticals has a market capitalization of $3.54 million and generates $23.99 million in revenue each year. The company earns $-8,280,000.00 in net income (profit) each year or ($4.16) on an earnings per share basis. Innovus Pharmaceuticals employs 27 workers across the globe.View Additional Information About Innovus Pharmaceuticals.

What is Innovus Pharmaceuticals' official website?

The official website for Innovus Pharmaceuticals is http://www.innovuspharma.com/.

How can I contact Innovus Pharmaceuticals?

Innovus Pharmaceuticals' mailing address is 8845 Rehco Road, San Diego CA, 92121. The company can be reached via phone at 858-964-5123 or via email at [email protected]

MarketBeat Community Rating for Innovus Pharmaceuticals (OTCMKTS INNV)

Community Ranking:  2.0 out of 5 (star star)
Outperform Votes:  80 (Vote Outperform)
Underperform Votes:  116 (Vote Underperform)
Total Votes:  196
MarketBeat's community ratings are surveys of what our community members think about Innovus Pharmaceuticals and other stocks. Vote "Outperform" if you believe INNV will outperform the S&P 500 over the long term. Vote "Underperform" if you believe INNV will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 6/17/2019 by MarketBeat.com Staff

Featured Article: Trade War

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel